Hip Pelvis.  2014 Mar;26(1):41-44. 10.5371/hp.2014.26.1.41.

Unusual Excessive Callus Formation in the Intertrochanteric Fracture Treated with Teriparatide

• Shin YS
• Jung HJ
• Savale AP
• Han SB

• KMID: 2054161
• DOI: http://doi.org/10.5371/hp.2014.26.1.41

Abstract

This is the first case report on the effects of teriparatide on the course of healing of an intertrochanteric hip fracture with unusually excessive callus formation even after discontinuation of treatment in an elderly woman. This case highlights the long-term effects of parathyroid hormone, even after administration of short-term, intermittent dosages for healing of osteoporotic fracture.

Keyword

Intertrochanteric fracture; Callus formation; Parathyroid hormone; Teriparatide

MeSH Terms

Aged
Bony Callus*
Female
Hip
Humans
Osteoporotic Fractures
Parathyroid Hormone
Teriparatide*
Parathyroid Hormone
Teriparatide

Figure

• 

  Fig. 1 Preoperative anteroposterior radiograph of the pelvis, hips, and femurs, showing osteoporotic, 4-part comminuted, displaced intertrochanteric fracture of the right hip of AO/OTA classification 31-A2.3 with varus external rotation deformity of the proximal femur.

• 

  Fig. 2 Immediate postoperative radiograph of the pelvis, hips, and femurs, showing somewhat reduced, stable fracture fixation with proximal femur intramedullary interlock nail with wound drain and urinary catheter in situ.

• 

  Fig. 3 Three-month postoperative radiograph of the pelvis, hips, and femurs, showing well-united fracture site with sufficient periosteal callus formation and stable intramedullary interlock nail in situ.

• 

  Fig. 4 One-year postoperative radiograph of the pelvis, hips, and femurs, showing well-united fracture site with excessive periosteal callus formation, which is an unusual phenomenon in normal fracture healing stages and the remodeling phase.

• 

  Fig. 5 At 6 postoperative months, the patient's radiographs showed abnormal excessive callus formation around the intertrochanteric fracture site, which is an unusual presentation.

Reference

1. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993; 14:690–709.

2. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005; 26:688–703.

3. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999; 14:960–968.

4. Skripitz R, Andreassen TT, Aspenberg P. Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber. A dose-response study. J Bone Joint Surg Br. 2000; 82:138–141.

5. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30:312–321.

6. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010; 25:404–414.

7. Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011; 93:1583–1587.